Last updated October 21, 2026. Approval line checked October 21, 2026. Compounding sources checked October 10, 2026.
FDA status
Not approved
Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.
FDA primary source on fileBy signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Animal Only. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 2/5. 310 PubMed citations indexed.
IGF-1 splice variant with unique E-domain peptide activating quiescent muscle satellite cells for hypertrophy and repair; acts locally at site of mechanical stress.
What the literature studies
Muscle Repair & Satellite Cell Activation
Evidence tier
Animal Only
Compounding record
503A Category 3
503A Category 3. FDA substance context: Mechano Growth Factor (MGF), non-pegylated: 503A Category 3 (inadequate supporting information). Distinct from PEG-MGF (PEGylated mechano growth factor), whose nomination was withdrawn; FDA still identifies potential significant safety risks for PEG-MGF. Neither establishes approval or compounding eligibility. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source checked October 10, 2026. This compounding label is separate from the approval line above.
no human safety data; potential for disproportionate local muscle growth.
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.